Evolus' Evolysse™ Form and Evolysse™ Smooth, injectable hyaluronic acid (HA) gels designed for dermal filling applications, have been approved by the FDA, demonstrating statistically superior longevity compared to Restylane®-L in a U.S. trial. The products incorporate Cold-X™ technology, designed to preserve the HA molecule's natural structure for longer-lasting, natural-looking results. Evolus, in partnership with Symatese, developed these products as part of a broader portfolio, following one of the largest clinical trial programs for an injectable HA technology, with over 2,000 patients globally evaluated.